Lupin has secured the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Ankleshwar facility in Gujarat, India. The EIR has been issued following the closure of a product-specific Pre-Approval Inspection conducted by USFDA from March 2 to March 7, 2026.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
